Albert Labs International Corp. ([CSE: ABRT], the “Company” or “Albert Labs”), a fully-integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet mental health needs, is pleased to announce the expansion of its drug discovery pipeline, broadening the Company’s product portfolio and clinical strategy to additional key jurisdictions and licence indications.
Albert Labs is committed to transforming the landscape of healthcare with its innovative platform of medicines. Offering a robust pipeline of product candidates meticulously designed to address urgent and clinical unmet medical needs, Albert Labs is poised to make a significant impact in the fields of mental health and oncology.
The Company has been reviewing multiple opportunities to expand its drug discovery and clinical strategy, focusing first on mental health and oncology, through naturally occurring bioactive molecules, which include:
- KRN-101, a natural, psilocybin-based, fixed-ratio, prescription-only medicine, which targets cancer-related distress allowing accelerated regulatory access through the major regulatory bodies, such as the MHRA/EMA in the United Kingdom and Europe, as well as the FDA in the United States.
- KRN-101 will also be developed for Alcohol Use Disorder as a secondary indication, pursuing accelerated regulatory access in Canada and Europe.
- Albert Labs has agreed to a Letter of Intent (LOI) with Cannabis Science, Inc. to review their CBIS 001, a cannabinoid-based drug asset for treating cancers. CBIS 001 has successfully completed drug discovery in conjunction with Harvard Medical School, with the results published in Frontier Oncology Journal. This LOI explores the potential of Albert Labs expertise taking CBIS 001 through pre-clinical studies in Portugal, Pharmacokinetic studies in Australia, and Real World Evidence accelerated regulatory access pathways in the United Kingdom.
- A clinical review spearheaded by industry-leading pre-clinical researcher, Dr Ricardo Dinis (University of Porto), of naturally occurring potential drug candidates with anxiolytic properties and a historically safe toxicity profile, with the potential for subsequent licence indications, which include anxiety, and insomnia.
Business of Albert Labs International Corp.
Albert Labs is a fully-integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet mental health needs. Its team of experts leverage advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which patient needs are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast-track clinical pathway focusing on Real World Evidence (RWE). RWE studies are a recognised clinical pathway, heavily used in oncology and recently, in the successful development of COVID-19 vaccines.
Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to its treatment. Albert Labs’ first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.
The company’s goal is to deliver effective medicines to those who suffer with their mental health in the shortest possible time without compromising safety and/or quality, while also providing significant returns to shareholders.
Albert Labs (CSE: ABRT) (FSE: VB50) is publicly listed on the Canadian Securities Exchange (CSE).
You can find more details about Albert Labs on our website here.
ON BEHALF OF THE BOARD OF DIRECTORS
Albert Labs International Corp.
Dr. Michael Raymont
Chief Executive Officer, Chairman
For further information please contact:
Tel: +1 778-819-0740 Tel: +44 1625 324 960
This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate. The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements. Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws.
Click here to connect with Albert Labs International Corp. [CSE: ABRT], to receive an Investor Presentation